Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

• Wondering if FMC at US$17.84 is a bargain or a value trap? This article breaks down what the current price really implies about the stock.
• The shares have returned 4.0% over the last 7 days and 26.3% over the last 30 days, yet the 1 year return sits at a 50.1% decline and the 3 and 5 year returns are 83.6% and 81.2% declines.
• Recent coverage has focused on FMC’s sharp long term share price pullback alongside its more recent short term rebound. This has put the stock back on the radar for investors reassessing risk and potential reward. Commentators have also highlighted how these moves have shifted attention toward whether the current price reflects the underlying business or mainly changing sentiment.
• FMC currently has a valuation score of 5 out of 6. The rest of this article will break down what that means across different valuation methods, while also pointing you to an even better way to think about the stock’s value at the end.

Find out why FMC’s -50.1% return over the last year is lagging behind its peers.

Approach 1: FMC Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes forecasts of a company’s future cash flows and discounts them back to today using a required rate of return, aiming to estimate what the business is worth right now.

For FMC, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections in US$. The latest twelve month free cash flow is a loss of $161.40 million, so the model assumes conditions change over time. Analyst estimates feed into the nearer term, with projected free cash flow of $177.45 million in 2028. Beyond the explicit analyst horizon, Simply Wall St extrapolates free cash flows out to 2035, keeping the growth pattern grounded in those earlier inputs.

Putting these projected cash flows together and discounting them back to today gives an estimated intrinsic value of about $23.70 per share. Versus the current share price of $17.84, this implies FMC trades at roughly a 24.7% discount, which points to the shares looking undervalued under this DCF framework.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests FMC is undervalued by 24.7%. Track this in your watchlist or portfolio, or discover 64 more high quality undervalued stocks.

FMC Discounted Cash Flow as at Apr 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for FMC.

Approach 2: FMC Price vs Sales

For many established, profitable companies, price based multiples are a practical way to gauge what the market is willing to pay for each unit of business performance. When earnings are volatile, P/S can be especially useful because sales tend to be less affected by short term swings in profitability.

What counts as a normal or fair P/S ratio depends on how investors see a company’s growth potential and risk. Higher expected growth or lower perceived risk can support a higher P/S, while lower growth or higher risk usually justifies a lower multiple.

FMC currently trades on a P/S of 0.64x. This is below the Chemicals industry average of 1.13x and below the peer group average of 1.25x. Simply Wall St’s Fair Ratio for FMC is 1.88x, which is its proprietary estimate of what the P/S might be given factors such as earnings growth, profit margins, industry, market cap and company specific risks.

Because the Fair Ratio adjusts for those company specific drivers, it offers a more tailored benchmark than simply comparing FMC to peers or the wider industry. Comparing the current 0.64x P/S to the 1.88x Fair Ratio suggests the shares trade at a discount on this measure.

Result: UNDERVALUED

NYSE:FMC P/S Ratio as at Apr 2026

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your FMC Narrative

Earlier it was mentioned that there is an even better way to think about valuation. That is where Narratives come in, letting you attach a clear story about FMC, your own view on its future revenue, earnings and margins, to a forecast and a Fair Value that you can compare directly with today’s price on Simply Wall St’s Community page. You might side with a more cautious FMC view that lines up with a Fair Value of about US$13.00 or a more optimistic view closer to US$74.11. As new news or earnings arrive, those Narratives update automatically so your buy or sell decisions stay tied to the latest information rather than a static model.

For FMC, however, we will make it really easy for you with previews of two leading FMC Narratives:

Start with the bullish view if you think the market is underappreciating the repair story and the value of FMC’s portfolio and balance sheet actions, or the bear view if you think regulatory change and slowing demand still have more work to do on the share price.

🐂 FMC Bull Case

Fair Value in this bullish narrative: US$18.12 per share.

Implied discount to this Fair Value at US$17.84: about 1.5% undervalued.

Analyst revenue growth assumption used: about 5.47% a year.

• Analysts in this camp expect demand for proprietary products and biologicals, along with growth in regions like Brazil and EMEA, to support higher revenue and better margins over time.
• They see cost restructuring, manufacturing efficiencies and portfolio shifts improving free cash flow and helping debt reduction, which supports the balance sheet.
• The fair value of about US$18.12 reflects these expectations, but it still factors in execution risks around regulation, generic competition and leverage.

🐻 FMC Bear Case

Fair Value in this bearish narrative: US$13.00 per share.

Implied premium to this Fair Value at US$17.84: about 37.2% overvalued.

Analyst revenue growth assumption used: about 2.07% a year.

• Analysts behind this view focus on regulatory bans, shifts toward organic and regenerative farming, and higher approval hurdles as long term headwinds for FMC’s conventional crop protection portfolio.
• They highlight reliance on a concentrated set of specialty actives, rising generic competition and pressure on pricing as constraints on future earnings power.
• The fair value of US$13.00 builds in only modest revenue growth and margin recovery, and assumes that sector and regulatory pressures continue to weigh on the share price over time.

If you want to see how your own expectations compare with either outcome, the full Narratives on Simply Wall St set out the detailed numbers behind each case along with the assumptions that drive those fair values.

See what the community is saying about FMC

Do you think there’s more to the story for FMC? Head over to our Community to see what others are saying!

NYSE:FMC 1-Year Stock Price Chart

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include FMC.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com